Biogen Inc. (LON:0R1B)
133.27
-1.28 (-0.95%)
At close: Jul 11, 2025
Biogen Employees
Biogen had 7,605 employees as of December 31, 2024. The number of employees increased by 35 or 0.46% compared to the previous year.
Employees
7,605
Change (1Y)
35
Growth (1Y)
0.46%
Revenue / Employee
999.05K GBP
Profits / Employee
150.55K GBP
Market Cap
13.95B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Genus | 3,500 |
Biogen News
- 6 days ago - Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress - GlobeNewsWire
- 6 days ago - Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress - Business Wire
- 7 days ago - FDA Approves New Dosing Schedule For Eli Lilly's Kisunla In Alzheimer's Treatment - Benzinga
- 7 days ago - What's Driving the Market Sentiment Around Biogen? - Benzinga
- 9 days ago - Biogen sees negative Q2 impact from IPR&D, milestone expenses - Seeking Alpha
- 16 days ago - Biogen starts phase 3 trial of felzartamab for kidney disease - Seeking Alpha
- 16 days ago - Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy - GlobeNewsWire
- 19 days ago - Biogen lauds benefits of higher dose Spinraza for spinal muscular atrophy - Seeking Alpha